GSMA Outlines New Developments for MWC19 Shanghai
16.5.2019 11:00:00 EEST | Business Wire | Press release
The GSMA today announced new developments for MWC19 Shanghai, including recently confirmed keynote and 4YFN speakers, Artificial Intelligence Accelerate Programme, leading players showcasing latest mobile technologies at the GSMA Innovation City, Seminars and Forums and newly joined exhibitors, partners and sponsors. Taking place 26 - 28 June 2019 at the Shanghai New International Expo Centre (SNIEC), the GSMA expects more than 60,000 professionals from over 110 countries and territories representing a wide range of industry sectors to attend.
“Intelligent Connectivity, encompassing 5G, AI, IoT and Big Data, is paving the way for a new era which is set to impact almost every aspect of our daily lives,” said John Hoffman, CEO, GSMA Ltd. “Across MWC19 Shanghai, attendees will have the opportunity to hear from leaders who are driving this innovation globally. They will have access to exciting experiences and discussions through the exhibition and specialised programmes such as Artificial Intelligence Accelerate Programme, Digital Leaders, Women4Tech, 4YFN and more. We look forward once again to welcoming the mobile industry to Shanghai.”
New Keynote Speakers Confirmed
The GSMA announced additional keynote speakers for the MWC19 Shanghai conference programme, including:
- Yang Jie, Executive Director and Chairman, China Mobile
- Jing Ulrich, Managing Director and Vice Chairman of Asia Pacific, JPMorgan Chase & Co.
- Cristiano Amon, President, Qualcomm
These executives join previously announced speakers including:
- Hooi Ling Tan, Co-Founder, Grab Group
- Mats Granryd, Director General, GSMA
- Ken Hu, Deputy Chairman, Huawei
- Greg Wyler, Chairman, OneWeb
- Sigve Brekke, President and CEO, Telenor Group
- Xu Ziyang, CEO, ZTE
For more information on the conference, including the agenda and keynote speakers, visit: www.mwcshanghai.com/conference-programmes/.
Headline Speakers at 4 Years From Now (4YFN)
Meet the headline speakers taking part in 4YFN’s start-up focused conference programme:
- Cindy Chow, Executive Director, Alibaba Entrepreneurs Fund
- Minjun Liang, Venture Partner, ATM Capital
- Michelle Wu, Chief Information Officer, General Electric Power
- Janet Tang, Chief Strategy Officer, Lenovo Group
- Chad Xu, CEO and Founding Partner, Shenzhen Valley Ventures
4YFN, the GSMA’s start-up programme, is extending its investor presence at the event by welcoming on board new Investors Club member Shenzhen Valley Ventures and bringing back long-term partner Cathay Innovation. Community partners Momentum Works, Tusstar and Chinaccelerator will bring innovative and exciting startups to the exhibition floor and the Discovery Area Stage, while Mobile World Capital will bring a delegation of Spanish startups and Sud de France will sponsor an exclusive VIP reception. A custom working lounge provided by Spaces will be open to all visitors.
For more information about 4YFN, visit: www.mwcshanghai.com/experiences/4yfn/.
First Artificial Intelligence Accelerate Programme at MWC Shanghai
New to MWC19 Shanghai, the Artificial Intelligence Accelerate Programme will host a range of activities that bring together stakeholders including policymakers, industry leaders, AI specialists, academia and start-ups, to discuss key policy forumulation, stimulate new innovations and explore how AI can be applied throughout the digital economy. The programme, held from 25-28 June, includes events such as AI in Network Seminar, AI Policy Roundtable, Think AI Summit, AI Trust Panels partnered with Digital Asia Hub - a think tank incubated by Harvard University and a number of workshops. For details about Artificial Intelligence Accelerate Programme, visit: www.mwcshanghai.com/about/get-involved/ai/.
GSMA Innovation City Showcasing Latest Mobile Technologies
Located in Hall N5, the GSMA Innovation City will once again put a spotlight on the latest leading mobile products and solutions and how they are positively impacting society and helping to create a better future. The City includes interactive demonstrations by new partners China Mobile Migu and Singtel, who join previously announced companies, including BICS, Huawei, myFC and Shanghai Ratta Smart Technology. The City will also host exhibits from the GSMA’s industry programmes including Future Networks, Identity and the Internet of Things. Demonstrations include how blockchain is helping to monetize the value of IoT data, how drones and unmanned boats are supporting environmental monitoring and how China’s mobile operators are using mobile authentication to help consumers make daily financial transactions. For more information about the GSMA Innovation City, visit: www.mwcshanghai.com/exhibition/gsma-innovation-city/.
Additional Exhibitors and Sponsors Confirmed for MWC19 Shanghai
Taking centre stage in Super Hall N3, leading industry players include China Information and Communication Technologies (CICT), China Mobile, China Telecom, Ericsson, New H3C, Nokia Shanghai Bell and ZTE will feature the application of 5G technology in the intelligent connected era. Newly confirmed exhibitors and sponsors for MWC19 Shanghai include Ericsson as the “Connectivity Event Theme Sponsor”, new exhibitors Apigate, Gemalto, FIME, Gosuncn Technology, Intracom Telecom, Korea Information and Technology Industry Association (KICTA), Microsoft China, SI-Tech join previously announced companies including Lenovo, Qualcomm, OPPO, Samsung, vivo, among others. For more information on the exhibition, visit: www.mwcshanghai.com/exhibition/.
DISPLAY CHINA 2019 Co-located For Second Year at MWC19 Shanghai
DISPLAY CHINA will be a concurrent event with MWC19 Shanghai for the second year in Hall E5 at the SNIEC and will promote the latest flexible and HD displays and future innovative applications. MWC Shanghai attendees holding VIP, Gold, All Exhibition or Press/Analyst passes will have access to Display China 2019. For more information about Display China, visit: www.mwcshanghai.com/exhibition/display-china/.
GSMA Forums and Seminars
The GSMA will host a range of forums and seminars at MWC19 Shanghai to provide insights and updates on key industry developments.
- GSMA Future IoT Convention, sponsored by Nokia Shanghai Bell and Sunsea AIoT
- 4th 5G Spectrum & Policy Forum, co-hosted by GSA
- eSIM Forum, sponsored by Valid
- Future Broadband Forum, co-hosted by C114
- 5G Network Forum
For more information on GSMA Forums and Seminars, visit: www.mwcshanghai.com/conference-programmes/forums-seminars/.
Register and Get Involved at MWC19 Shanghai
Registration to attend MWC19 Shanghai is now open, for information on registration and pass types, please visit: www.mwcshanghai.com/attend/register/
For more information on MWC19 Shanghai, including how to attend, exhibit, partner or sponsor, visit www.mwcshanghai.com. Follow developments and updates on MWC19 Shanghai through our social media channels – follow us on Twitter at @GSMA and use #MWC19, get regular updates through our LinkedIn Showcase Page at www.linkedin.com/showcase/mwcshanghai/, and follow us on Facebook at www.facebook.com/mwcshanghai. In China, you can follow us on Sina Weibo weibo.com/mwcshanghai or search “GSMA_MWCS” in WeChat.
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005325/en/
Contact information
Media Contacts:
For the GSMA
April Tsui
+852 2533
9956
atsui@webershandwick.com
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
MWC19 Shanghai Press Office
press@mwcshanghai.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
